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Staphylococcus aureus is a well recognized pathogen with global distribution. In recent years 
community-associated, methicillin-resistant S. aureus has emerged as an increasing cause of 
severe infections among adults and children. Herein, a case is reported of a previously healthy, 
19-month-old male, who presented with empyema necessitans and acute osteomyelitis due to a 
community-associated, methicillin-resistant, S. aureus strain. This report highlights the evolving 
epidemiology of S. aureus, as important pathogen in the community as well as the hospital 
setting, and the importance of establishing appropriate guidelines for diagnosis, management 
and surveillance of this public health problem.
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Empiema necessitans y osteomielitis aguda secundaria a una infección por Staphylo-
coccus aureus resistente a meticilina asociado a la comunidad
Staphylococcus aureus es uno de los principales patógenos a nivel mundial. Durante los últimos 
años se ha reportado un incremento en el número de casos de S. aureus resistente a la meticilina 
adquiridos en la comunidad, tanto en niños como en adultos de los Estados Unidos y de otras 
partes del mundo.
En el presente trabajo reportamos un caso de empiema necessitans y osteomielitis aguda 
en un niño de 19 meses de edad previamente sano. El presente reporte resalta la cambiante 
epidemiología de S. aureus tanto en la comunidad como en el medio hospitalario y la importancia 
de establecer guías apropiadas para el diagnóstico, el tratamiento y la vigilancia de este relevante 
problema de salud pública.
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Methicillin-resistant Staphylococcus aureus 
(MRSA) is an important, globally distributed, 
nosocomial pathogen. Recently, numerous 
cases of community associated MRSA (CA-
MRSA) strains, which differ phenotypically and 
genotypically from the nosocomial isolates, have 
been reported in adult and pediatric populations. 
Most published CA-MRSA cases present 
potentially life threatening infections, such as soft 
tissue infections, pneumonia and endocarditis. 
Herein, a case is reported of a previously healthy 
infant with empyema necessitans and acute 
osteomyelitis due to CA-MRSA strain. In a review 
of the literature, appropriate tools are identified 
for CA-MRSA diagnosis and management.
Case definition
The case definition used for distinguishing CA-
MRSA from healthcare-associated MRSA (HA-
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that met all of the following criteria: 1) the MRSA 
diagnosis was made in the outpatient setting 
or by positive culture for MRSA within 48 hours 
after admission to the hospital, 2) no medical 
history of MRSA infection, 3) no medical history 
in the past year of hospitalization, surgery or 
permanently inserted catheters or medical 
devices that penetrate the skin.
Case report
A previously healthy 19-month-old, African 
American male was seen at a community hospital 
emergency room (Houston, TX) because of a 
five-day history of fever and chest tenderness. A 
diagnosis of left side pneumonia was made and 
the patient was discharged, with on azithromycin 
and acetaminophen.
Three days later he returned to the emergency 
room with persistent fever, pain over his left chest 
wall and worsening of respiratory symptoms. 
He was given albuterol, atrovent and one dose 
of ceftriaxone and vancomycin; later, he was 
transferred to the Hermann Hospital (Houston TX). 
No history of previous hospitalizations, antibiotic 
use, or sick contacts were documented. 
The patient appeared to be in moderate distress; 
he had a temperature of 98°F, a pulse of 168 
beats per minute and a respiratory rate of 60 
per minute. Chest examination revealed a 3 x 
4 cm mass in the left chest wall between the 
midclavicular and axillary lines, approximately 
between the third and fifth intercostal spaces. 
Breath sounds over the entire left side of the 
chest were decreased. The remainder of the 
examination was unremarkable. 
Laboratory data showed a white blood count of 
8,200 with 15% neutrophils, 13% bands, 42% 
lymphocytes and 11% lymphocytes. Hemoglobin 
was 11.8 g/dl, hematocrit 35.3% and platelet 
count of 328,000 mm3. 
A chest radiograph showed complete opacification 
of the left hemithorax consistent with pneumonia 
and effusion (figure 1). A contrast computed 
tomography scan of the chest showed a large 
left empyema with total collapse of the left upper 
lobe and extension into the left chest wall. A 
diagnosis of empyema necessitans was made 
on the basis of the scan and clinical presentation; 
subsequently, a left thoracospic decortication 
was performed with removal of fibrin-purulent 
exudates, and ceftriaxone plus vancomycin were 
administrated.
Given the history of bilateral pulmonary 
nodules compatible with septic emboli, two 
echocardiograms were performed and were 
negative for endocarditis. Blood cultures at 
admission and cultures from the purulent fluid 
extracted from lungs and from the subcutaneous 
and chest wall collections were positive for S. 
aureus infection which was resistant to oxacillin 
and erythromycin. The isolate was sensitive to 
clindamycin, gentamycin, rifampin,trimethoprim-
sulfamethoxazole (TMP-SMX), vancomycin, and 
Figure 1. Chest X-ray and CT scan of the chest.
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tetracycline. Ceftriaxone was discontinued, 
and gentamycin was administered with the 
vancomycin for two weeks. 
During his hospitalization, local swelling and 
tenderness in the right thigh was found and 
thrombosis of right femoral and popliteal vein 
was documented; therefore, anticoagulation 
therapy with heparin was initiated. Additionally, 
magnetic resonance imaging showed early 
stages of acute osteomyelitis of right distal femur 
(figure 2); therefore, vancomycin was continued 
for 36 days, followed by oral clindamycin. The 
patient was discharged after resolution of the 
lung infection and maintained on oral clindamycin 
to complete the treatment for osteomyelitis. 
Anticoagulation with warfarin was continued for 
three months. At follow up, the patient appeared 
completely recovered.
Discussion
Empyema necessitans is a rare clinical 
condition, which was initially recognized by 
Gullan De Baillon in 1640 (1). This complication 
of empyema is characterized by the extension of 
pus from the pleural cavity into the thoracic wall 
to form a mass of purulent fluid in the adjacent 
soft tissues. The most common sites of extension 
are the anterior chest wall, esophagus and 
mediastinum and alternative areas of extension 
include breast, diaphragm, retroperitoneum, 
and groin (2). Empyema necessitans is usually 
reported in adults; and  rarely in pediatric patients 
(1-3). The majority of the cases are associated 
with Mycobacterium tuberculosis, Streptococcus 
pneumoniae, S. aureus, Streptococcus milleri, 
Pseudomonas cepacia, and Mycobacterium 
avium-intracellulare. Non infections etiologies 
include lymphomas, bronchogenic carcinoma, 
mesothelioma and sarcomas (1,4-5). Two cases 
of empyema necessitans due to CA-MRSA have 
been reported in otherwise healthy children 
(5,6).
Currently, CA-MRSA is one of the most common 
causes of pneumonia in all age groups (7-10). 
These cases are characterized by high fever, 
hypotension, leucopenia and multilobar infiltrates 
that usually progress into abscess/empyema. 
Metastatic pulmonary infections have become 
more frequent among infants with invasive 
staphylococci disease, especially among those 
with bone and joint infections (similar to the 
current report) (11). Furthermore, an increased 
frequency of deep venous thrombosis (DVT) 
associated with bone infections has been 
reported (11). Therefore, when the history and 
physical examination suggest metastatic disease, 
laboratory and diagnostic imaging evaluation are 
recommended for confirmation.
However, routine performance of echocardio-
graphy for individuals with S. aureus bacteremia 
is controversial (12-14). Nevertheless,  evaluation 
of children for endocarditis seems prudent when 
blood culture results are persistently positive or 
when findings consistent with pulmonary emboli 
are noted on chest radiograph images (15).
The primary approaches to CA-MRSA infections 
management include surgical drainage, along 
with cultures for bacterial identification and 
drug susceptibility testing, followed by adequate 
antimicrobial therapy (16). The primary therapy 
in the management of empyema necessitans 
includes aggressive drainage of abscesses 
Figure 2. Magnetic resonance image of the right femur. The 
arrow shows signs of osteomyelitis involving the distal right 
femoral metaphysis (arrow), plus myositis of the right thigh 
and subcutaneous cellulitis as well.
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or other purulent collections by thoracotomy, 
decortications or wide surgical drainage, and 
adequate antimicrobial therapy. 
The specific choice of antistaphylococcal agent 
depends on the site of the infection and the 
susceptibility of the isolates to antimicrobials. 
Empirical therapy with intravenous vancomycin 
and oxacillin is recommended. Once sensitivities 
are known and MRSA infection is confirmed, 
vancomycin is the recommended therapy, if 
the infection is due to methicillin-susceptible S. 
aureus, oxacillin is the drug of choice (17). 
Clindamycin is an antibiotic option for the treat-
ment of serious infections caused by CA-MRSA. 
However, CA-MRSA strains that are susceptible 
to clindamycin but resistant to erythromycin 
may have the phenotype of in vitro inducible 
macrolide-lincosamide-streptogramin B (iMLS) 
resistance. This may be due to the presence of 
erythromycin ribosomal methylase genes (ermC 
or ermA). For these strains, a high rate of mutation 
for constitutive resistance occurs; these mutants 
are strongly selected during clindamycin therapy. 
In vitro iMLS can be detected in erythromycin-
resistant CA-MRSA strains through the use of 
double-disk diffusion assay denominated D test 
(18) (figure 3A).  In the current case, the strain 
had a negative D test (figure 3B). 
TMP-SMX can be an ideal agent for the 
management of uncomplicated CA-MRSA 
infections; this agent is available in oral and 
intravenous formulations and has excellent 
tissue penetration. The current review led to the 
conclusion that TMP-SMX may be effective for 
S. aureus infections with a low bacterial burden. 
However, for severe staphylococcal infections 
with high bacterial loads, such as tricuspid 
valve endocarditis, bacteremia, pneumonia, 
and bone and joint infections, TMP-SMX is not 
recommended as a monotherapy (17). 
Rifampin distributes well into many body tissues 
and may act synergistically with other antibiotics 
(e.g. vancomycin). Hence, it is a useful supportive 
therapy in treating deep-seated staphylococcal 
infections such as endocarditis, osteomyelitis 
and empyema (19). Linezolid was equal to 
vancomycin for the treatment of infections 
caused by resistant gram-positive bacteria. It 
has the ability to inhibit toxin production in PVL-
producing strains, as does clindamycin, fusidic 
acid and rifampin (20). 
Daptomycin, tigecycline, ceftobiprole, oritavancin, 
telavancin and dalbavancin are potential 
treatment options, but data supporting use in 
children is limited.
Currently, the majority of the CA-MRSA pediatric 
infections in the United States and Colombia 
are caused by the USA300 and USA400 strains 
(previously MW2) (19,20, In: American Society 
for Microbiology. Abstracts of the 47th Inter-
Science Conference on Antimicrobial Agents 
and Chemotherapy. Abstract C2-145. p.101).
Figure 3. D-test. A. Representation of a positive D-test (D + phenotype). B. Representation of a negative D-test (D - 
phenotype). E: erythromycin; CC: clindamycin.
A B
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CA-MRSA infections are widely disseminated 
in the world. The new strain causes a wide 
number of life-threatening infections (skin and 
soft tissue infections, necrotizing pneumonia, 
acute osteomyelitis, py omisitis, endocarditis 
and meningitis) in patients with no apparent risk 
factors for MRSA acquisition (21).
The prevalence of CA-MRSA varies geogra-
phically.  According to a study in 2005 from the 
Center for Disease Prevention and Control, CA-
MRSA comprised 8-20% of all MRSA isolates. 
An annual disease incidence of 25.7/100,000 
was recorded in Atlanta, Georgia compared with 
a rate of 18/100,000 in Baltimore, Maryland. The 
incidence was higher among children <2 years 
old (22). 
In Colombia, the first report of CA-MRSA was of 
two healthy adults who presented with severe skin 
and soft infections in 2005 (23). Subsequently, 
multiple cases of bloodstream and soft tissue 
infections were indentified in adults and children 
from Cali and Cartagena (American Society for 
Microbiology. In: Abstracts of the 47th Inter-
Science Conference on Antimicrobial Agents 
and Chemotherapy. Abstract C2-145. p. 101). 
In Houston, Texas, the number of CA-MRSA 
infections has increased markedly over the past 
decade. The most recent report from Division of 
Pediatrics Infectious Diseases, Department of 
Pediatrics, University of Texas Medical School 
at Houston showed that 67% of CA-MRSA 
infections among hospitalized children were 
abscesses and complicated pneumonias (24).
The capacity of CA-MRSA to cause severe 
infections is probably due to multiple cell surface-
associated and secreted virulence factors. The 
Panton-Valentine leukocidin (PVL) induces 
polymorphonuclear cell death by necrosis or by 
apoptosis and it has been strongly associated 
with necrotizing pneumonia and osteomyelitis 
(25,26). The arginine catabolic mobile element 
(ACME) allows staphylococci to grow and 
survive within the host, whereas the oligopeptide 
permease (the second element of the ACME) 
contributes to nutrient uptake, quorum sensing, 
pheromone transport, chemotaxis, eukaryotic 
cell adhesion, binding of serum components, 
and expression of virulence determinants (26). 
Enterotoxins K and Q (superantigens) lead to the 
typical clinical findings of CA-MRSA infections 
such as fever, hypotension, multiple organ failure 
and disseminated intravascular coagulation (26). 
The collagen adhesion protein leads to greater 
adherence to host tissue, especially collagen 
(11). Additionally, a group of secreted peptides 
in CA-MRSA have the ability to lyse human 
neutrophils, thereby compromising a major 
cellular defense against CA-MRSA (27).
The determinants of methicillin resistance in S. 
aureus are mediated by the gene mecA, which 
has been localized on the chromosome of S. 
aureus. The mecA gene encodes a penicillin-
binding protein (PBP2a), which has low affinity for 
all beta-lactam antibiotics (28). The mecA gene 
is localized in a mobile genetic element called 
staphylococcal cassette chromosome (SCC). 
This element has been classified in six different 
types (I-VI) according with the combination of the 
chromosome recombinase genes (28). The type 
I, II and III SCCmec have been mainly described 
in nosocomial strains, whereas type IV, V and 
VI have been described in the CA-MRSA strains 
(28). Normally, the SCCmec IV-VII harbor lower 
determinants of resistance. This explains why 
CA-MRSA isolates remain susceptible to a 
wide range of antibiotics such as erythromycin, 
clindamycin, gentamycin, rifampin, TMP-SMX, 
vancomycin, and tetracycline.
Prevention is a powerful strategy, and recognition 
of a population at risk is the first step in control the 
emergence of this new threat. Most CA-MRSA 
infections have been identified in populations 
that have extreme physical contact such as 
kindergarten children, incarcerated or homeless 
people, intravenous drug users and athletes. 
Consequently, keeping skin injuries clean, short 
fingernails and changing personal hygiene 
materials may assist in the prevention of CA-
MRSA infections (29,30). 
A second strategy for individuals in a high risk 
environment is to bathe twice a week for 15 
minutes in water with regular strength Clorox® 
(one teaspoon per gallon of water). This 
disinfectant appears to reduce rates of recurrent 
Biomédica 2009;29:506-12
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infections in at-risk populations with a history 
of skin of soft tissue infections (29). Currently, 
CA-MRSA is not a reportable disease; however, 
if an outbreak is suspected, the serious nature 
of the disease recommends that public health 
authorities be alerted.
Conclusion
CA-MRSA has emerged as an important 
pathogen that produces a significant number of 
severe infections with metastatic complications in 
otherwise healthy individuals. The management 
procedures include rapid diagnosis, appropriate 
incision and drainage (when needed) and 
vigorous antimicrobial therapy.
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